Dolzhenko A T
Biull Eksp Biol Med. 1982 Mar;93(3):29-31.
Experiments with slices of the rat cortex were made to study the interaction between the ability of the antidepressants to inhibit the reverse uptake of 14C-noradrenaline and to inhibit its presynaptic release. The antidepressants studied are distributed into 3 groups according to the ratio of effective concentrations that block the uptake and enhance the release of 14C-noradrenaline from the slices. The first group includes the antidepressants (melipramine, chlorimipramine, Lu 5-003, Lu 3-010, S-394, pyrazidol) that have a ratio close to I and in whose mechanism of aminopotentiating action the main component is unlikely to be distinguished. The second group with a ratio less than I is represented by the substances (nortryptyline, desipramine) whose mechanism of the aminopotentiating action is determined by the inhibitory effect on the neurotransmitter reverse uptake. As to the 3d group antidepressants (thyroliberin, iprindol, noveril, C-356, C-395, amitryptyline), of great importance is their effect on the presynaptic neurotransmitter release from the terminals of the axons of noradrenergic neurons.
进行了大鼠皮质切片实验,以研究抗抑郁药抑制14C - 去甲肾上腺素逆向摄取的能力与其抑制其突触前释放之间的相互作用。根据阻断摄取并增强切片中14C - 去甲肾上腺素释放的有效浓度之比,将所研究的抗抑郁药分为3组。第一组包括抗抑郁药(丙咪嗪、氯米帕明、Lu 5 - 003、Lu 3 - 010、S - 394、吡唑朵),其比例接近1,且在其氨基增强作用机制中,主要成分不太可能被区分出来。第二组比例小于1,以物质(去甲替林、地昔帕明)为代表,其氨基增强作用机制由对神经递质逆向摄取的抑制作用决定。至于第三组抗抑郁药(促甲状腺素释放激素、茚满丙二胺、诺米芬辛、C - 356、C - 395、阿米替林),它们对去甲肾上腺素能神经元轴突终末突触前神经递质释放的影响非常重要。